"Bio-Works is very pleased to be able to support Nemysis in its mission to create products which prevent the negative side effects of nutrient disorders and deficiency," said Lone Carlbom, CEO of Bio-Works Technologies. "This order is evidence that our strategy to create unique purification products is in line with the needs of a diversifying platform of biotherapeutic molecules."

"Bio-Works provided us with an excellent affinity resin and related support to optimize the purification of our enzyme and speed up the downstream operations. Nemysis strongly believes the collaboration with Bio-Works will continue as a strategic relationship in its production of the best quality of this valuable finished product." said Cristina Comelli, CSO at Nemysis Ltd.

Nemysis Ltd. is a Specialty Pharmaceutical Company focused on therapeutic solutions for highly prevalent nutritional disorders and deficiencies, delivering products to the healthcare market.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Lone Carlbom, CEO, e-mail: lone.carlbom@bio-works.com, phone: +46(0)8-502 705 84.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.